These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
135 related articles for article (PubMed ID: 28863055)
1. The Last State to Grant Nurse Practitioners DEA Licensure: An Education Improvement Initiative on the Florida Prescription Drug Monitoring Program. Kellams JR; Maye JP J Addict Nurs; 2017; 28(3):135-142. PubMed ID: 28863055 [TBL] [Abstract][Full Text] [Related]
2. Evaluating Emergency Department Opioid Prescribing Behaviors After Education About Mandated Use of the Pennsylvania Prescription Drug Monitoring Program. Martello J; Cassidy B; Mitchell A J Addict Nurs; 2018; 29(3):196-202. PubMed ID: 30180006 [TBL] [Abstract][Full Text] [Related]
3. Evaluation of Florida physicians' knowledge and attitudes toward accessing the state prescription drug monitoring program as a prescribing tool. Gershman JA; Gershman JA; Fass AD; Popovici I Pain Med; 2014 Dec; 15(12):2013-9. PubMed ID: 24931295 [TBL] [Abstract][Full Text] [Related]
4. Trends in Florida's Prescription Drug Monitoring Program registration and utilization: Implications for increasing voluntary use. Delcher C; Wang Y; Young HW; Goldberger BA; Schmidt S; Reisfield GM J Opioid Manag; 2017; 13(5):283-289. PubMed ID: 29199394 [TBL] [Abstract][Full Text] [Related]
5. The Role of Continuing Medical Education in Increasing Enrollment in Prescription Drug Monitoring Programs. Finnell JT; Twillman RK; Breslan SA; Schultz J; Miller L Clin Ther; 2017 Sep; 39(9):1896-1902.e2. PubMed ID: 28865800 [TBL] [Abstract][Full Text] [Related]
6. Attitudes of Florida pharmacists toward implementing a state prescription drug monitoring program for controlled substances. Fass JA; Hardigan PC J Manag Care Pharm; 2011; 17(6):430-8. PubMed ID: 21787028 [TBL] [Abstract][Full Text] [Related]
7. Alaska nurse practitioners' barriers to use of prescription drug monitoring programs. Christianson H; Driscoll E; Hull A J Am Assoc Nurse Pract; 2018 Jan; 30(1):35-42. PubMed ID: 29757920 [TBL] [Abstract][Full Text] [Related]
8. Perception of prescription drug monitoring programs as a prevention tool in primary medical care. Goodin AJ; Brown JD; Delcher C; Freeman PR; Talbert J; Henry SG; Roussos-Ross D Res Social Adm Pharm; 2020 Sep; 16(9):1306-1308. PubMed ID: 30935769 [TBL] [Abstract][Full Text] [Related]
9. A survey of Physicians' Perspectives on the New York State Mandatory Prescription Monitoring Program (ISTOP). Blum CJ; Nelson LS; Hoffman RS J Subst Abuse Treat; 2016 Nov; 70():35-43. PubMed ID: 27692186 [TBL] [Abstract][Full Text] [Related]
10. Impact of prescription drug monitoring programs (PDMPs) on opioid utilization among Medicare beneficiaries in 10 US States. Moyo P; Simoni-Wastila L; Griffin BA; Onukwugha E; Harrington D; Alexander GC; Palumbo F Addiction; 2017 Oct; 112(10):1784-1796. PubMed ID: 28498498 [TBL] [Abstract][Full Text] [Related]
11. Prescription drug monitoring program design and function: A qualitative analysis. Rutkow L; Smith KC; Lai AY; Vernick JS; Davis CS; Alexander GC Drug Alcohol Depend; 2017 Nov; 180():395-400. PubMed ID: 28978492 [TBL] [Abstract][Full Text] [Related]
12. Characteristics of state prescription drug monitoring programs: a state-by-state survey. Manasco AT; Griggs C; Leeds R; Langlois BK; Breaud AH; Mitchell PM; Weiner SG Pharmacoepidemiol Drug Saf; 2016 Jul; 25(7):847-51. PubMed ID: 27061342 [TBL] [Abstract][Full Text] [Related]
13. Effect of Florida's Prescription Drug Monitoring Program and Pill Mill Laws on Opioid Prescribing and Use. Rutkow L; Chang HY; Daubresse M; Webster DW; Stuart EA; Alexander GC JAMA Intern Med; 2015 Oct; 175(10):1642-9. PubMed ID: 26280092 [TBL] [Abstract][Full Text] [Related]
14. Substance Use Stigma, Primary Care, and the New York State Prescription Drug Monitoring Program. Allen B; Harocopos A; Chernick R Behav Med; 2020; 46(1):52-62. PubMed ID: 30726167 [TBL] [Abstract][Full Text] [Related]
15. Research to support optimization of prescription drug monitoring programs. Doyle S; Leichtling G; Hildebran C; Reilly C Pharmacoepidemiol Drug Saf; 2017 Nov; 26(11):1425-1427. PubMed ID: 28905438 [TBL] [Abstract][Full Text] [Related]
16. Impact of prescription drug-monitoring program on controlled substance prescribing in the ED. McAllister MW; Aaronson P; Spillane J; Schreiber M; Baroso G; Kraemer D; Smotherman C; Gray-Eurom K Am J Emerg Med; 2015 Jun; 33(6):781-5. PubMed ID: 25842283 [TBL] [Abstract][Full Text] [Related]
17. State-level prescription drug monitoring program mandates and adolescent injection drug use in the United States, 1995-2017: A difference-in-differences analysis. Earlywine JJ; Hadland SE; Raifman J PLoS Med; 2020 Sep; 17(9):e1003272. PubMed ID: 32976539 [TBL] [Abstract][Full Text] [Related]
18. The Impact of Prescription Drug Monitoring Programs and Prescribing Guidelines on Emergency Department Opioid Prescribing: A Multi-Center Survey. Pomerleau AC; Nelson LS; Hoppe JA; Salzman M; Weiss PS; Perrone J Pain Med; 2017 May; 18(5):889-897. PubMed ID: 26995800 [TBL] [Abstract][Full Text] [Related]
19. The current utilization and perceptions of prescription drug monitoring programs among emergency medicine providers in Florida. Young HW; Tyndall JA; Cottler LB Int J Emerg Med; 2017 Dec; 10(1):16. PubMed ID: 28421563 [TBL] [Abstract][Full Text] [Related]
20. Clinicians' Use of Prescription Drug Monitoring Programs in Clinical Practice and Decision-Making. Leichtling GJ; Irvine JM; Hildebran C; Cohen DJ; Hallvik SE; Deyo RA Pain Med; 2017 Jun; 18(6):1063-1069. PubMed ID: 27794549 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]